Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: Impact of body weight and immunogenicity

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 9, 2010, Pages 596-607

  Xu, Z H ^a   Lee, H ^b   Vu, T ^b   Hu, C ^a   Yan, H ^a   Baker, D ^a   Hsu, B ^a   Pendley, C ^a   Wagner, C ^a   Davis, H M ^a   Zhou, H ^a  

^a CENTOCOR INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ankylosing spondylitis; Golimumab; Monoclonal antibody; Population pharmacokinetics; Tumor necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; DRUG ANTIBODY; GOLIMUMAB; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALCOHOL CONSUMPTION; ANKYLOSING SPONDYLITIS; ARTICLE; ASIA; ASIAN; BODY WEIGHT; CANADA; CAUCASIAN; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; EUROPE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEGRO; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES; ADOLESCENT; BIOLOGICAL MODEL; IMMUNOLOGY; METABOLIC CLEARANCE RATE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; SPONDYLITIS, ANKYLOSING;

EID: 77956930841     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48596     Document Type: Article

References (40)

1. Abbott Laboratories. Humira: Package insert. Abbott Park, IL; 2009.
2. Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996; 26: 526-538.
3. Centocor Ortho Biotech, Inc. Remicade: Package insert. Malvern, PA; 2009.
4. Centocor Ortho Biotech, Inc. Simponi: Package insert. Horsham, PA; 2009.
5. Davis JC Jr, Revicki D, van der Heijde DM et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007; 57: 1050-1057.
6. Davis JC Jr, van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48: 3230-3236.
7. Elan Pharmaceuticals. Tysabri: Package insert. South San Francisco, CA; 2008.
8. Ette EI, Williams PJ, Kim YH et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003; 43: 610-623.
9. Feng Y, Pollock BG, Coley K et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008; 66: 629-639.
10. Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2009; DOI: 10.1002/pst.403.
11. Immunex. Enbrel: Package insert. Thousand Oaks, CA; 2009.
12. Inman RD, Davis JC Jr, van der Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum. 2008; 58: 3402-3412.
13. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007; 82: 17-20.
14. Kavanaugh A, McInnes I, Mease Pet al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60: 976-986.
15. Kay J, Matteson EL, Dasgupta B et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double- blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008; 58: 964-975.
16. Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009; 68: 789-796.
17. Khan MA. Thoughts concerning the early diagnosis of ankylosing spondylitis and related diseases. Clin Exp Rheumatol. 2002; 20: 6-10.
18. Lee PI. Design and power of a population pharmacokinetic study. Pharm Res. 2001; 18: 75-82.
19. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks- NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004; 75: 85-94.
20. Maitre PO, Buhrer M, Thomson D et al. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991; 19: 377-384.
21. Mascelli MA, Zhou H, Sweet R et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007; 47: 553-565.
22. McGonagle D, Marzo-Ortega H, Benjamin M et al. Report on the second international enthesitis workshop. Arthritis Rheum. 2003; 48: 896-905.
23. Montgomery DC, Peck EA. Introduction to linear regression analysis. New York, NY: JohnWiley & Sons; 1982.
24. Parke J, Holford NH, Charles BG. Aprocedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999; 59: 19-29.
25. Post TM, Freijer JI, Ploeger BA et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008; 35: 185-202.
26. Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009; 68: 1739-1745.
27. Savic R, Karlsson M. Shrinkage in empirical Bayes estimates for diagnostics and estimation: problems and solutions. 16th Annual Meeting of the Population Approach Group in Europe. Copenhagen, Denmark; 2007.
28. Savic R, Wilkins J, Karlsson M. (Un)informativeness of empirical Bayes estimate-based diagnostics. The AAPS Journal. 2006; 8: 3360.
29. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007; 47: 1104-1118.
30. Sun YN, Lu JF, Joshi A et al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005; 45: 468-476.
31. Ternant D, Aubourg A, Magdelaine-Beuzelin C et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008; 30: 523-529.
32. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo- controlled trial (ASSERT). Arthritis Rheum. 2005; 52: 582-591.
33. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54: 2136-2146.
34. Wang DD, Zhang S, Zhao H et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009; 49: 1012-1024.
35. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009; 21: 211-215.
36. Xu Z, Vu T, Lee H et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009; 49: 1056-1070.
37. Yim DS, Zhou H, Buckwalter M et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2005; 45: 246-256.
38. Zhang X, Aubin JE, Inman RD. Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis. Curr Opin Rheumatol. 2003; 15: 387-393.
39. Zhou H, Jang H, Fleischmann RM et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007; 47: 383-396.
40. Zhu Y, Hu C, Lu M et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009; 49: 162-175.